A breast cancer drug combo showed a median of 21.5 months without progression in patients without liver metastases.

Celcuity reported VIKTORIA-1 subgroup data showing median PFS of 21.5 months for triplet therapy, 11.5 months for doublet, vs 9.1 months for alpelisib+fulvestrant in PIK3CA MT HR+/HER2- ABC without liver mets. TEAE discontinuations were lower for Celcuity's treatments.

Celcuity Inc. (CELC) reported Phase 1b/2 trial results for gedatolisib combined with darolutamide in metastatic castration-resistant prostate cancer. The study showed median radiographic progression-free survival of 15.7 months for patients who received prior abiraterone and 9.1 months for those who received prior enzalutamide. The company plans to begin the Phase 2 portion of the study in the first half of 2027.

Celcuity Inc. (CELC) reported Phase 1b/2 data for gedatolisib + darolutamide in mCRPC, showing median rPFS of 15.7 months post-abiraterone. Phase 2 trials are expected to begin in H1 2027. The data adds a new tumor setting to gedatolisib's program.

Celcuity Inc. (CELC) reported updated Phase 1b/2 study results for gedatolisib in mCRPC patients. 82.2% of abiraterone-pretreated patients had no progression at six months. Median rPFS was 15.7 months. Phase 2 study expected in 2027.

Celcuity Inc. shares rose 7.78% after Cantor Fitzgerald initiated coverage with an overweight rating and a $140 price target, citing growth potential of its breast cancer drug, Revtorpyk. The company will present key clinical data at the ESMO Congress this weekend. Analysts are bullish, with price targets ranging from $130 to $177, despite a 50% stock decline over six months.

Cantor Fitzgerald initiated coverage of Celcuity with an Overweight rating and $140 price target, implying 127.4% upside from the Oct 21 close. Analysts cite strong market potential and encouraging clinical data for gedatolisib (Revtorpyk), projecting peak sales of $2.7B for second-line treatment and $1.6B for first-line breast cancer.